[
  {
    "ts": null,
    "headline": "Lantheus Holdings (NasdaqGM:LNTH) Joins FIBRE Consortium To Transform Fibrotic Disease Treatment",
    "summary": "The launch of the FIBRE Consortium, which includes Lantheus Holdings (NasdaqGM:LNTH) collaborating with Pfizer and Lumina Pharmaceuticals, aims to improve treatment for fibrotic diseases using advanced imaging biomarkers, potentially strengthening the company's market position. Additionally, Lantheus' presentation of oncology radiodiagnostic data may have bolstered investor confidence in its diagnostic capabilities. Despite a 5% stock price increase, the market remained largely flat amid...",
    "url": "https://finnhub.io/api/news?id=baa44c0ce3ab2aaec0380a6cad0a2daab601cc98f0082f939bd2a52da14c6e6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750440729,
      "headline": "Lantheus Holdings (NasdaqGM:LNTH) Joins FIBRE Consortium To Transform Fibrotic Disease Treatment",
      "id": 135445010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The launch of the FIBRE Consortium, which includes Lantheus Holdings (NasdaqGM:LNTH) collaborating with Pfizer and Lumina Pharmaceuticals, aims to improve treatment for fibrotic diseases using advanced imaging biomarkers, potentially strengthening the company's market position. Additionally, Lantheus' presentation of oncology radiodiagnostic data may have bolstered investor confidence in its diagnostic capabilities. Despite a 5% stock price increase, the market remained largely flat amid...",
      "url": "https://finnhub.io/api/news?id=baa44c0ce3ab2aaec0380a6cad0a2daab601cc98f0082f939bd2a52da14c6e6d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Joins FIBRE Consortium To Advance Fibrosis Treatment Through Innovative Imaging",
    "summary": "The recent formation of the FIBRE Consortium, a collaboration involving Pfizer (NYSE:PFE) and other pharmaceutical partners, aims to pioneer advancements in fibrotic disease management. Alongside this, Pfizer's submission of a New Drug Application for vepdegestrant to treat breast cancer and significant progress in colorectal and prostate cancer therapies were key developments. Over the past month, Pfizer's stock saw a price increase of 4%. The company's performance appeared aligned with...",
    "url": "https://finnhub.io/api/news?id=8e85f403e530b3ef955b2d5acdf5e1ca43934e1ba5f65a4de836445ece4078fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750440072,
      "headline": "Pfizer (NYSE:PFE) Joins FIBRE Consortium To Advance Fibrosis Treatment Through Innovative Imaging",
      "id": 135445011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The recent formation of the FIBRE Consortium, a collaboration involving Pfizer (NYSE:PFE) and other pharmaceutical partners, aims to pioneer advancements in fibrotic disease management. Alongside this, Pfizer's submission of a New Drug Application for vepdegestrant to treat breast cancer and significant progress in colorectal and prostate cancer therapies were key developments. Over the past month, Pfizer's stock saw a price increase of 4%. The company's performance appeared aligned with...",
      "url": "https://finnhub.io/api/news?id=8e85f403e530b3ef955b2d5acdf5e1ca43934e1ba5f65a4de836445ece4078fd"
    }
  },
  {
    "ts": null,
    "headline": "Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.",
    "summary": "Five years ago, scientists and investors were excited about gene therapy offering one-and-done cures for deadly diseases. Today, much of the enthusiasm has dried up.",
    "url": "https://finnhub.io/api/news?id=4010113ed3005ff1bd12be9f245a836ee25b2d9a0cae0889c9409c6bd2043f9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750433220,
      "headline": "Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.",
      "id": 135441698,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Five years ago, scientists and investors were excited about gene therapy offering one-and-done cures for deadly diseases. Today, much of the enthusiasm has dried up.",
      "url": "https://finnhub.io/api/news?id=4010113ed3005ff1bd12be9f245a836ee25b2d9a0cae0889c9409c6bd2043f9e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?",
    "summary": "Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.",
    "url": "https://finnhub.io/api/news?id=b46854599b3c289f46af7ea3da087a54549effccc363f2b7aba2aae7a7b5432a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750428060,
      "headline": "Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?",
      "id": 135440911,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.",
      "url": "https://finnhub.io/api/news?id=b46854599b3c289f46af7ea3da087a54549effccc363f2b7aba2aae7a7b5432a"
    }
  },
  {
    "ts": null,
    "headline": "Is Trending Stock Pfizer Inc. (PFE) a Buy Now?",
    "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=1779e46de9a0fdfc8e14efe12e6b32deb1561c63ffdced5dd8a6b5fda800b8b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750424404,
      "headline": "Is Trending Stock Pfizer Inc. (PFE) a Buy Now?",
      "id": 135440912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=1779e46de9a0fdfc8e14efe12e6b32deb1561c63ffdced5dd8a6b5fda800b8b8"
    }
  },
  {
    "ts": null,
    "headline": "Perceptive Discovery and Pfizer Launch the FIBRE Consortium to Transform Fibrosis Drug Development",
    "summary": "Perceptive Discovery announced the launch of the FIBRE Consortium, a bold pre-competitive collaboration with Pfizer, Lantheus, and Lumina Pharmaceuticals. This pioneering initiative aims to...",
    "url": "https://finnhub.io/api/news?id=78e73d8062fafbdb8247eee2594c7b41432fc1ec87542a316172e42ea5c02d68",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750419355,
      "headline": "Perceptive Discovery and Pfizer Launch the FIBRE Consortium to Transform Fibrosis Drug Development",
      "id": 135436129,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Perceptive Discovery announced the launch of the FIBRE Consortium, a bold pre-competitive collaboration with Pfizer, Lantheus, and Lumina Pharmaceuticals. This pioneering initiative aims to...",
      "url": "https://finnhub.io/api/news?id=78e73d8062fafbdb8247eee2594c7b41432fc1ec87542a316172e42ea5c02d68"
    }
  },
  {
    "ts": null,
    "headline": "Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases",
    "summary": "Beam Therapeutics shows promising BEACON trial results in SCD, backed by strong cash reserves and pipeline momentum. See why BEAM stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=82a5837db4f997bf7342a6395c98a284614dd423fc25e150f258cb0b629c2450",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750414069,
      "headline": "Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases",
      "id": 135430453,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215629289/image_2215629289.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Beam Therapeutics shows promising BEACON trial results in SCD, backed by strong cash reserves and pipeline momentum. See why BEAM stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=82a5837db4f997bf7342a6395c98a284614dd423fc25e150f258cb0b629c2450"
    }
  },
  {
    "ts": null,
    "headline": "I'm Buying Dividend Giants At Huge Discounts",
    "summary": "I'm Buying Dividend Giants At Huge Discounts",
    "url": "https://finnhub.io/api/news?id=c4e55e0c5d02211dda3cc076c7a0eb04974633f7f0e66792fdfe7e6012c11cbb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750410000,
      "headline": "I'm Buying Dividend Giants At Huge Discounts",
      "id": 135425473,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=c4e55e0c5d02211dda3cc076c7a0eb04974633f7f0e66792fdfe7e6012c11cbb"
    }
  },
  {
    "ts": null,
    "headline": "Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn't Rule It Out",
    "summary": "Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn't Rule It Out",
    "url": "https://finnhub.io/api/news?id=17d9d4c57a2a9598401e59f2389e855f50181d0aed0ce0d39fc40f25191951a6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750408200,
      "headline": "Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn't Rule It Out",
      "id": 135424524,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=17d9d4c57a2a9598401e59f2389e855f50181d0aed0ce0d39fc40f25191951a6"
    }
  },
  {
    "ts": null,
    "headline": "The Retirement Pyramid: The Near-Perfect Blueprint For Maximum Income And Minimum Stress",
    "summary": "The Retirement Pyramid: The Near-Perfect Blueprint For Maximum Income And Minimum Stress",
    "url": "https://finnhub.io/api/news?id=128c04651eef7acf30c8172f40819a7b63b6ad270bb02f4418868c4ab550977b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750404600,
      "headline": "The Retirement Pyramid: The Near-Perfect Blueprint For Maximum Income And Minimum Stress",
      "id": 135424141,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=128c04651eef7acf30c8172f40819a7b63b6ad270bb02f4418868c4ab550977b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: An Offensive Play For A Bear Market",
    "summary": "Pfizer: An Offensive Play For A Bear Market",
    "url": "https://finnhub.io/api/news?id=672f847fccc662f863fd4c8f32c52ebe4e684cbdb558fc400fa8e5e09d4e8182",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750394511,
      "headline": "Pfizer: An Offensive Play For A Bear Market",
      "id": 135421484,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=672f847fccc662f863fd4c8f32c52ebe4e684cbdb558fc400fa8e5e09d4e8182"
    }
  }
]